Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT314 + BNT327
- Development stage
- Phase 2
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BNT314 + BNT327 is an investigational combination therapy for solid tumors, including metastatic colorectal cancer and lung cancers. BNT314 is a novel immune-activating agent designed to enhance the body’s immune response against cancer, while BNT327 is a bispecific monoclonal antibody targeting both PD-L1 and VEGF-A, combining checkpoint inhibition with anti-angiogenic activity. Together with chemotherapy, this combination aims to synergistically boost antitumor responses by simultaneously modulating the tumor microenvironment and immune system. Both agents are developed by BioNTech, with BNT327 also partnered for development and commercialization globally with Bristol Myers Squibb. Early-stage clinical trials have reported encouraging efficacy, good disease control, and a manageable safety profile in colorectal cancer (Phase 1/2) and extensive-stage small cell lung cancer (Phase 2)[1][3][5][7].
- Other names
- pumitamigBMS986545BMS-986545BMS 986545
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on BNT314 + BNT327.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT314 + BNT327.